{'fraction_non_alphanumeric': 0.016069221260815822, 'fraction_numerical': 0.002472187886279357, 'mean_word_length': 6.297297297297297, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Advancing Women's Health Care

Abstract Premenstrual dysphoric disorder (PMDD) currently affects 3%-8% of menstruating women. The apparent biological pathogenesis of this controversial disorder makes psychopharmacologic treatment an efficacious intervention. Biopsychosocial aspects of premenstrual distress indicate that psychotherapy aimed at providing women with skills to alleviate their severe psychological and physical premenstrual symptoms may also be viable treatment options. This article reviews the factors associated with PMDD, as well as the efficacy of psychopharmacological and psychotherapeutic treatment options. Recommendations include the need for consensus regarding the use of the term PMDD, as well as the dissemination of accurate information about PMDD symptoms and treatment options.